774243-59-3Relevant academic research and scientific papers
Biosynthesis of Fluorinated Peptaibols Using a Site-Directed Building Block Incorporation Approach
Rivera-Chávez, José,Raja, Huzefa A.,Graf, Tyler N.,Burdette, Joanna E.,Pearce, Cedric J.,Oberlies, Nicholas H.
supporting information, p. 1883 - 1892 (2017/06/28)
Synthetic biological approaches, such as site-directed biosynthesis, have contributed to the expansion of the chemical space of natural products, making possible the biosynthesis of unnatural metabolites that otherwise would be difficult to access. Such m
Structure-based design of novel human Pin1 inhibitors (I)
Guo, Chuangxing,Hou, Xinjun,Dong, Liming,Dagostino, Eleanor,Greasley, Samantha,Ferre, RoseAnn,Marakovits, Joseph,Johnson, M. Catherine,Matthews, David,Mroczkowski, Barbara,Parge, Hans,VanArsdale, Todd,Popoff, Ian,Piraino, Joseph,Margosiak, Stephen,Thomson, James,Los, Gerrit,Murray, Brion W.
scheme or table, p. 5613 - 5616 (2010/04/30)
Pin1 is a member of the cis-trans peptidyl-prolyl isomerase family with potential anti-cancer therapeutic value. Here we report structure-based de novo design and optimization of novel Pin1 inhibitors. Without a viable lead from internal screenings, we de
Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting NIMA (PIN1)
-
Page/Page column 40; 62-63, (2010/02/14)
Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell proliferation, infectious diseases, and neurodegenerative brain disorders, by administering effective amounts of such compounds.
PHOSPHATE/SULFATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN INTERACTING NIMA (PIN1)
-
Page 62, (2010/02/08)
Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell proliferation, infectious diseases, and neurodegenerative brain disorders, by administering effective amounts of such compounds.
